Events

Meet the Precision
AQ team at
ISPOR Europe 2025

Glasgow, Scotland, UK | 9-12 November, 2025

Schedule time to meet our Global HEOR & Access Strategy team at ISPOR Europe 2025 in Glasgow, Scotland, UK from 9-12 November 2025.

Whether it’s building the right evidence or refining your value story, we’re here to simplify the journey from development to patient care – so your therapies can reach the patients who need them most.

Complete the form to book a meeting, and we’ll reach out to confirm the details.

book a meeting

Precision AQ's Posters at ISPOR EU 2025

Poster Session 1

HPR209: The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

Richard Macaulay, BA, PhD; David Carr, BSc, PhD

download

Poster Session 2

HTA97: Cost-Effectiveness Modeling Challenges and Trends in the Neoadjuvant and Perioperative Settings: A Review of NICE Oncology Submissions

Chloi Theriou, MSc; Eleni Pavlidou, MSc; Alicia Nicole Pepper, PhD

download

HTA89: CONITEC in Action: A Trend Analysis of CONITEC’s Evaluation Outcomes From 2020 to Present Day

Dominika Meszarosova, MSc; Daniel Bacheschi, BS

download

Poster Session 3

MSR127: Implementing Simultaneous Maximum Acceptable Risk Thresholds (SMARTs) in Discrete Choice Experiments (DCE): A Feasible Approach to Quantify Tolerance for Multiple Risks

Laura Panattoni, PhD; Joshua Coulter, MA; Grace Gahlon, ScM; Brett Hauber, PhD; Natalie Land, MPH; Anh Thy H. Nguyen, PhD, MSPH; Thomas Flottemesch, PhD; Melissa Culhane Maravic, MPH, PhD; Peter Hur, PharmD, MBA

download

HTA217: Landscape Analysis of Initiatives to Improve Access to Orphan Drugs Led by Industry, Patient, and Academic Stakeholders

Richard Macaulay, PhD; Anika Mavinkurve, MPH; Joel Iff, PharmD, PhD; Susan J Ward, PhD

download

HPR132: Leveling the Field: How the MFN Could Transform Drug Pricing?

Rebecca Andrews; Anika Mavinkurve, MPH

download

Poster Session 4

HSD97: Real-World Treatment Patterns Among Patients with Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)

Grace Gahlon, ScM; Shailja Vaghela, MPH; Lorena Lopez-Gonzalez, PhD; Craig Freyer, PharmD, BCOP; Shelby Corman, PharmD, MS; Huan Huang, PhD

download

HTA233: Middle East NICE Move Towards Standardized Health Technology Assessment

Jorge Jacob, MSc; Dominika Meszarosova, MSc

download

Poster Session 5

HTA321: The Interim Acceptance and Ultra-Orphan Pathways in Scotland: An Update

Ethan J. Prince, MBiochem; Richard Macaulay, PhD

download

HPR229: Unintended Consequences of MFN Pricing: Global Access Risks and Revenue Impact

Eve Jamali, MSc; Daniel Bacheschi, MBA

download

HPR218: Through a Glass Darkly: The What, How, and What Now for Global Net Price Transparency

David Carr, PhD; Dimitrios Tzaras, MPharm; Alexander Grosvenor, BSc; Victor Moran, MSc

download

HTA368: When Less Is More: Learnings From a Recent NICE Submission Utilizing a Novel Predictive Individual-Level Surrogacy Approach to Predict Overall Survival (OS) in the Absence of Trial-Level Evidence

Liza Mastikhina, MSc; Andrea Berardi, MSc; Dylan Maciel, MSc; Shannon Cope, MSc

download